Email :
Contact : (321) 445-1969

Role of Immunotherapy in Post Transplantation Lymphoproliferative Disorders


Post transplantation Lymphoproliferative Disorder is the most severe complication of both solid organ transplantation and hematopoietic stem cell transplantation. It arises in 1-15% of transplanted patients and involves malignant and uncontrolled B cell proliferation. It is due to immunodeficiency resulting from the therapeutic immuno supression in the recipients. The common risk factors of PTLD are age, viral infection including EBV, HCV, CMV, human leukocyte antigen (HLA) alleles and the type of the transplanted organ. The aim of this review is to discuss the patho physiology of the PTLD and various Immuno therapies for PTLD including FDA approved drug such as Brentuximab Vedotin and other drugs that are still in clinical trial.

Download Pdf